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Background. We investigated the integron types and their relation with antibiotic resistance among A. baumannii isolates collected
from intensive care unit patients, Babol, north of Iran. Methods. In this cross-sectional study, a total of 73 bronchoalveolar lavage
samples were obtained from patients in ICU. Susceptibility testing was performed by disk diffusion method. Types of integrons
were identified by an integrase gene PCR. Results. In total, 47.9% A. baumannii isolates were recovered from the BAL samples. All
isolates were resistant to ceftazidime. 91.4% and 58.3% of isolates were MDR and XDR, respectively. The rate of colistin resistance
with the 𝐸-test was 5.7%. Molecular analysis of class I, II, and III integrons showed that 25.7%, 88.6%, and 28.6% of the isolates
carried the intI, intII, and intIII genes, respectively. Discussion. Our results show that different classes of integrons are commonly
spread among A. baumannii strains and these genomic segments can play an important role in the acquisition of MDR and XDR
phenotypes. So monitoring drug resistance in A. baumannii isolates with the use of int gene PCR is very important to plan specific
infection control measures to prevent the spread of MDR-AB and XDR-AB in Iran’s hospitals.
1. Introduction
Multidrug-resistant Acinetobacter baumannii (MDR-AB) is
an important opportunistic pathogen responsible for severe
hospital-acquired infections (HAIs), particularly patients
admitted to the intensive care unit (ICU) [1]. MDR-AB
infections especially pneumonia and bacteremia show a high
mortality rate (30% to 75%) and require prolonged hospital
stays in intensive care units (ICUs) [2]. In the ICU, themortal-
ity rate associated with A. baumannii is 54%. The majority of
infections are originated from epidemic outbreaks. Appear-
ance of extensively drug-resistant A. baumannii (XDR-AB)
limits the therapeutic options and causes a serious concern
to HAI control. For a period of 5 years (2005–2010), the
frequency of XDR-AB in clinical isolates was increased from
15% to more than 41%. Control of MDR-AB and XDR-AB
infections is an important issue for clinical microbiologists
and physicians. Treatment of A. baumannii has become
difficult because many isolates are now resistant to a wide
range of antimicrobial agents [3, 4].
An important factor that influences the development of
multiresistance phenotype is the acquisition ofmobile genetic
elements (MGEs). Antibiotic-resistant elements in Acineto-
bacter strains are commonly carried on MGEs, such as the
R plasmids, transposons (TEs), integrons (Int), and genomic
islands (GEIs) [5]. Integrons are conserved sequences (3󸀠-CS
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and 5󸀠-CS) of DNA that are able to acquire gene cassettes,
which can carry antibiotic resistance genes, by site-specific
recombination [6]. These genetic segments are considered
by the presence of an intI gene (integrase), a recombination
site (attI), and a promoter (PC) [7]. The most common types
of integrons are the transportable class I (Tn402 deriva-
tives) integron, followed by class II and class III integrons,
respectively. Class I integrons harbor numerous antimicro-
bial resistance gene cassettes encoding broad-spectrum 𝛽-
lactamase, dfr (dihydroflavonol-4-reductase/trimethoprim),
qacEΔ1 (disinfectants and tetravalent ammonium com-
pounds), sul1 (sulfonamide), and aminoglycoside-modifying
enzymes (AMEs). Integrons of class II are located in Tn7 and
3󸀠-CSwhich contains five tns genes and are responsible for the
mobility of TE. Integrons of class III located in transposons
have also been described, but the 3󸀠-CS is still not well defined
[8].
MDR phenotype occurs in A. baumannii when different
integrin-borne antibiotic resistance elements coexist, giving
rise toMDR gene cassettes [9, 10]. Due to the high prevalence
of this infection, as well as various profiles of drug resistance
in different geographical areas, a study on the prevalence and
antibiotic resistance pattern in different part of the world is
essential.These data would provide useful information on the
spread of resistance elements and the possibility of choosing
appropriate treatment strategies. So, the aim of this study was
to determine the frequency of type I, II, and III integrons in
A. baumannii isolates recovered from bronchoalveolar lavage
(BAL) samples obtained from hospitalized patients in ICU
ward, Babol, north of Iran [11].
2. Materials and Methods
2.1. Setting. The Ayatollah Rouhani hospital is a 372-bed
hospital and is one of themost equipped teaching therapeutic
centers affiliated to the Babol Medical University in north of
Iran. This study was approved by the ethical committee of
Babol University of Medical Sciences for Research Analysis.
In this analytical cross-sectional study, based on previous
studies and confidence interval 95% and using equation 𝑛 =
𝑧2𝑃(1 − 𝑃)/𝑑2, a total of 73 nonrepetitive and nonduplicative
BAL samples were collected from ICU patients from May to
November 2015.
2.2. Inclusion Criteria. Clinical findings of pneumonia are as
follows: new radiographic infiltrate and two of the three
subsequent criteria: fever [body temperature ≥ 38.0∘C] or
hypothermia temperature < 35.0∘C [rqb], purulent bronchial
secretion, and WBCs > 10,000/mm3 or <3,000/mm3 [12].
2.3. Exclusion Criteria. Contraindications to bronchoscopy
include the following: (1) Po2 < 75mmHg even with an
inspired oxygen fraction of 100%; (2) acute cardiac arrhyth-
mia; and (3) bronchospasm [12].
2.4. Chest Radiograph (Chest X-Ray). A portable chest radio-
graph was obtained prior to, and on the same day as,
bronchoscopic sampling. Infiltration of lung (chest X-ray)
was included as a criterion for hospital admission. The
radiographwas reviewed and interpreted by a staff radiologist
and pulmonary disease specialist [12].
2.5. Procedure and Specimen Collection (BAL Collection).
Patients were commonly sedated with IV midazolam before
bronchoscopic procedure. The fraction of inspired oxygen
was increased to 100%, and positive end-expiratory pressure
was limited to 8 cm H
2
O. The bronchoscope used was the
Pentax FB15X (Pentax Instruments, Tokyo, Japan). Bron-
choscopic BAL samples were collected by pulmonologist by
wedging the tip of a fiber optic bronchoscope in the subseg-
mental bronchus of the most compromised lobe seen in chest
X-ray or, in cases of diffuse radiologic presentation, in the
posterior bronchus of the lower lobe. As little topical lido-
caine as possible was used so as not to interfere with bacterial
growth (never >20mg per bronchus). Aspiration of secre-
tions by the bronchoscope was avoided. This procedure was
repeated in the contralateral lung, and samples were pre-
served at ambient temperatures or 4∘C before being trans-
ported to themicrobiology laboratory within 2 h of collection
[12, 13].
2.6. Quantitative Cultures. Quantitative cultures were pro-
cessed according to the standard laboratory protocol. Sample
pairs collected were diluted in tryptic soy broth (Merck, Co.,
Germany) plated at final dilutions of 10−3 and 10−4 onto eosin
methylene blue agar, chocolate agar and blood agar (Merck,
Co., Germany) plates and then incubated at 35∘C under 5%
CO
2
. Gram staining was performed on 1 drop of undiluted
BAL fluid. Final colony counts were determined after 48 h.
Potential pathogens present at ≥1 × 104 CFU/ml were consid-
ered clinically significant, and subsequent identification and
antimicrobial susceptibility testing were performed. Isolates
detected at ≥1 × 103 and <1 × 104 CFU/ml were presumptively
identified, and antimicrobial susceptibility testing was not
performed.The following were considered etiologic agents of
pneumonia: (1) bacteria with >104 CFU/mL in BAL quanti-
tative culture (according to clinical judgment, >103 CFU/mL
was considered positive) and (2) demonstration by direct
microscopic examination of BAL fluid [12, 13].
2.7. Bacterial Isolates. After transferring all samples to the
Department of Microbiology in the medicine faculty, A.
baumannii strains were recognized based on conventional
biochemical and microbiological tests including Gram stain-
ing, oxidase and catalase test, motility, oxidation of glucose,
hydrolysis of esculin, decarboxylation of lysine, hydrolysis
of arginine, reduction of nitrate, citrate utilization, oxida-
tive/fermentative glucose (O/F) test, and growth ability at
44∘C. Negative result for oxidase test, no motility, nonfer-
mentation, and growth in temperature of 42–44∘C were
considered as the elementary criteria for A. baumannii
recognition [14]. In order to confirm the identity of strains,
the presence of gyrB gene was assessed using PCR [15, 16].
The isolates were preserved in −80∘C in brain-heart infusion
broth (Merck, Co., Germany) containing glycerol 50% v/v
until the molecular analysis.
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Table 1: Primer sequences, PCR product sizes, and PCR programs for replication of class I, II, and III integrons.
Genes Primer sequence (5󸀠 → 3󸀠) PCR product (bp) PCR program Reference
IntI-I F-TCTCGGGTAACATCAAGGR-AGGAGATCCGAAGACCTC 243
5min at 94∘C; 35 cycles (1min at 94∘C,
1min at 53∘C, and 30 sec at 72∘C); 5min
at 72
[9]
IntI-II F-TTATTGCTGGGATTAGGCR-ACGGCTACCCTCTGTTATC 233
5min at 94∘C; 30 cycles (1min at 94∘C,
1min at 50∘C, and 1min at 72∘C); 10min
at 72∘
[10]
IntI-III F-AGTGGGTGGCGAATGAGTGR-TGTTCTTGTATCGGCAGGTG 600
5min at 94∘C; 30 cycles (1min at 94∘C,
1min at 50∘C, and 1min at 72∘C); 10min
at 72∘C
[10]
2.8. Antimicrobial Susceptibility Testing. Antimicrobial sus-
ceptibility testing was performed on Mueller-Hinton agar
(MHA) (Merck, Co., Germany) by agar disk diffusion (DD)
method as recommended by the Clinical and Laboratory
Standards Institute (CLSI document M100-S14) [17]. The
tested antibiotics were as follows: amikacin (AK; 30𝜇g),
ciprofloxacin (CP; 5𝜇g), ceftazidime (CAZ; 30 𝜇g), gentam-
icin (GM; 10 𝜇g), imipenem (IMP; 10 𝜇g), meropenem (MER;
10 𝜇g) and piperacillin/tazobactam (PTZ; 100/10 𝜇g) (MAST
diagnostics,Merseyside, UK).A. baumanniiATCC 17978was
used as a positive quality control (PQC) and P. aeruginosa
ATCC 25853 and E. coli ATCC 25922 were used as a negative
quality control (NQC) in this study.
2.9. Minimum Inhibitory Concentration (MIC). All isolates
were tested for colistin (CS) susceptibility by𝐸-test according
to the manufacturer’s guidelines (Liofilchem SRL, Italy).
Suspension of each isolate in Mueller-Hinton broth, adjusted
to the density of a 0.5 McFarland standard, was swabbed
in three directions to ensure uniform growth onto Mueller-
Hinton agar plates. An 𝐸-test CS strip (ranging from 0.016
to 256mg/ml) with interpretative criteria (susceptible (S),
≤2 𝜇g/ml; resistant (R), ≥4 𝜇g/ml) was used for each plate
when the agar surface was completely dry, and the plates
were incubated at 35∘C for 16–20 h.The minimum inhibitory
concentration (MIC) value was considered at the point
of complete inhibition of all growth, including hazes. The
interpretive criteria used were those established in Clinical
and Laboratory Standards Institute standard [14].
2.10. PCR Amplification and Sequencing. The PCR technique
were performed by the DNA amplification device master
cycler gradient (Eppendorf Co., Hamburg, Germany) for
detection of intI-I, intI-II, and intI-III genes. Whole-cell
(genomic) DNA was extracted from each strain using a high
pure PCR template preparation kit (Roche Co. in Germany).
The integron encoding gene classes and PCR programs are
listed in Table 1. PCR was performed in a whole volume of
25 𝜇l. PCRmixture contained 2 𝜇l of 10x PCR buffer, 1.5 DNA
template, 0.8 𝜇l MgCl
2
, 0.6 𝜇l dNTPs, 1.5 𝜇l of each primer,
0.7 IU of Taq DNA polymerase (Ampliqon Co., Denmark),
and 14.9 𝜇l of sterile distilled water. Amplification products
were electrophoresed on 1.5% agarose gels at 5 V/cm. Gels
were stained with ethidium bromide (EtBr) (0.5 𝜇g/ml)
and visualized on a UV trans-illuminator (Vilber Lourmat,
Cedex, France). The amplicon sizes were determined by
comparison with a DNA size marker (100-bp DNA ladder,
Fermentas). Direct sequencing of the PCR products was
performed in both directions using an ABI3730XL DNA
analyzer (Applied Biosystems, Forster, USA). Nucleotide
sequence data were analyzed at the National Center for Bio-
technology Information (NCBI), available at the website
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
2.11. Statistical Analysis. SPSS version 23 (SPSS, Inc., Chicago,
IL, USA) was employed for statistical analysis. Descriptive
statistics and Pearson’s chi-square tests were used to evaluate
the correlation between various classes of integrons and
antimicrobial resistance. Statistical significance was defined
as 𝑃 value less than 0.05.
3. Results
Mean of patients ages was 54.5 years (range, 17 to 92 years).
32 (43.8%) of them were female and 41 (56.2%) were male.
The mean APACHE II (acute physiology and chronic health
evaluation II) index was 16.2 at ICU admission (range, 7 to
31). Mean duration of hospitalization until BAL performance
was 14.3 days (range, 4 to 48 days). The main reasons for
admission to ICU were as follows: neurologic emergencies
in 23 patients (31.5%); respiratory failure in 19 (26.0%);
cardiocirculatory emergencies in 14 (19.2%); other infections
in 3 (4.1%); hematologic disorders in 3 (4.1%); trauma in 3
(4.1%); septic shock in 2 (2.7%); renal failure in 2 (2.7%);
diabetes in 2 (2.7%); malignancy in 1 (1.4%), and acute
abdomen in 1 (1.4%).
Forty-nine of 73 BALs (67.1%) presented >104 CFU/mL
in BAL quantitative culture. The three BALs (4.8%) that
presented between 103 and 104 CFU/mLwere also considered
positive. Total positivity was 52 of 73 (71.2%); 49 of these
52 positive (67.1%) had >104 CFU/mL. There were no cases
of bacterial growth with <103 CFU/mL. Twenty-one cases
(28.7%) did not present bacterial growth (Table 2).
A. baumannii isolates (𝑛 = 35; 47.9%) were recovered
from the BAL samples (𝑛 = 73). The highest resistance rate
was related to CAZ (100%) (Table 3). In the current study,
MDR-AB is defined as resistance to more than three classes
of antibiotics. XDR-AB is regarded as the isolate that is resist-
ant to 3 classes of antibiotics defined above (MDR) as well
4 BioMed Research International
Table 2: Bacterial etiologic agents.
Agents All BALs
Mono (%) Poly (%) Total (%)
A. baumannii 30 (41.1%) 5 (6.8%) 35 (48%)
Pseudomonas aeruginosa 3 (4.1%) 1 (1.9%) 4 (5.5%)
Staphylococcus aureus 2 (2.7%) 2 (2.7%) 4 (5.5%)
Klebsiella pneumoniae 1 (1.4%) 0 (0.0%) 1 (1.4%)
Escherichia coli 0 (0.0%) 1 (1.4%) 1 (1.4%)
Enterobacter cloacae 0 (0.0%) 1 (1.4%) 1 (1.4%)
Serratia marcescens 0 (0.0%) 2 (2.7%) 2 (2.7%)
Stenotrophomonas maltophilia 1 (1.4%) 0 (0.0%) 1 (1.4%)
MRCoNS 1 (1.4%) 0 (0.0%) 1 (1.4%)
Streptococcus pneumoniae 2 (2.7%) 0 (0.0%) 2 (2.7%)
Mono = unique isolated agent; Poly = polymicrobial infection; MRCoNS =
methicillin resistant coagulase-negative Staphylococcus.
Table 3: Antibiotics resistance patterns among Acinetobacter iso-
lates.
Antibiotics R (%) I (%) S (%)
Amikacin (AN) 32 (91.4) 0 (0.0) 3 (8.6)
Gentamicin (GM) 30 (85.7) 1 (2.9) 4 (11.4)
Ciprofloxacin (CP) 33 (94.3) 0 (0.0) 2 (5.7)
Ceftazidime (CAZ) 35 (100) 0 (0.0) 0 (0.0)
Imipenem (IPM) 33 (94.3) 2 (5.7) 0 (0.0)
Meropenem (MEN) 33 (94.3) 1 (2.9) 1 (2.9)
Piperacillin-
tazobactam
(PIP-TZ)
32 (91.4) 1 (2.9) 2 (5.7)
I = intermediate; R = resistance; S = susceptible.
as to carbapenems. Finally, pan-drug-resistant A. bauman-
nii (PDR-AB) is the XDR isolate that is also resistant to
tigecycline and polymyxins. According to the results of the
antimicrobial susceptibility test, 91.4% and 58.3% of the
isolates were MDR and XDR. The rates of CS resistance with
the 𝐸-test method in all A. baumannii studied strains were
determined 5.7% (𝑛; 2 of 35) (Figure 1).
Molecular detection of class I, II, and III integrons was
performed by amplification of intI, intII, and intIII genes in all
A. baumannii strains using PCRmethod.The results revealed
that 94.3% (𝑛; 33/35) of the isolates carried the int gene.
Molecular analysis of class I, II, and III integrons showed
that 25.7% (𝑛; 9), 88.6% (𝑛; 31), and 28.6% (𝑛; 10) of isolates
carried the intI, intII, and intIII genes, respectively. The
coexistence of intI/intII and intI/intII/intIII in isolates was in
order 22.9% (𝑛; 8) and 8.6% (𝑛; 3). Two (5.7%) of all isolates
were int-negative. The correlation of class I, II, and III inte-
grons and antibiotic resistance profile are shown in Table 4.
Nucleotide sequence data reported in the current study has
been deposited in the PubMed/NCBI/GenBank nucleotide
sequence databank under the accession numbers KX122025.1,
KX122026.1, KX122027.1, KX122028.1, and KX122029.1.
4. Discussion
A. baumannii is an important opportunistic bacterium caus-
ing severe HAIs with highmortality rates due to its wide drug
resistance. Integrons are vital in enabling the A. bauman-
nii genome to capture and accumulate many antimicrobial
resistance genes. Because of the MDR phenotype and the
trend to spread in the hospital environment, A. baumannii
has a special clinical significance requiring epidemiological
monitoring as a measure to control the spread of HAIs
[18].
In line with Gomes et al. [12], Zaccard et al. [13], and
Nomanpour et al. [19] studies, considering 104 CFU/mL as the
cutoff and including the cases with bacterial growth between
103 and 104 CFU/mL, 28 of all 52 positive BALs (53.8%)
presented more than one isolate, which means polymicrobial
infections. The most frequently encountered pathogens were
associated with two different strains of A. baumannii (48%)
and between P. aeruginosa (5.5%) and MRSA (5.5%), with
three cases of each association.
Our findings showed that all these strains were resistant
to CAZ. DD method results showed 91.4% and 58.3% of
the isolates were MDR and XDR, respectively. These results
are in agreement with the Ghajavand et al. study [20]. In
a parallel study piloted in Taipei, Taiwan, 25 XDR-AB were
found during two years of study [21]. This contrast may be
due to the geographical distance and/or the different levels
of hygiene. The majority of the strains were sensitive to CS,
regarded as the last resort against MDR-AB, probably due
to the fact that CS has not been broadly used in Iran; thus,
the corresponding selection pressure has not been established
on this bacterial species. 𝐸-test MIC value showed that 5.7%
(𝑛; 2) of isolates were resistant to CS. This data are similar
to Vakili et al. [14]. All CS-resistant isolates were positive
for class II integron. No significant association was observed
between CS-resistant isolates and class II integron.
Integrase-encoding genes were found in 33 (94.3%) of the
35 isolates. Our data showed that the prevalence of class I, II,
and III integrons was 25.7%, 88.6%, and 28.6%, respectively.
In the strains that had all the three classes of integrons, resis-
tance to all the antibiotics tested was observed. Two samples
(5.71%) did not contain any integrons but were still resistant
to CP and CAZ, which indicates that resistance genes could
also be transmitted by other elements such as plasmids, TEs,
and bacteriophages. In the study carried by Ramı´rez et al.,
the frequency of class I and II integrons was 42% and 68%,
respectively [22]. Also, Kamalbeik et al. showed that 7.5%
and 67.5% of the strains contained class I and II integrons,
respectively [23]. In the studies carried out by Ramı´rez et al.
[24] andMartins et al. [25], the prevalence of class II Integron
was 23% and 41.7%, respectively. In the research conducted
by Taherikalani et al. (Tehran at 2012) [26] andMoammadi et
al. (west of Iran at 2012) [27] the frequency of class I, II, and
III integrons was 85%, 14%, and 0%, and 97%, 31%, and 0%,
respectively. These findings are in contrast with our results
and may be related to the difference in source of samples,
level of hygiene, and geographical areas. So, it might be due
to stiff search-and-destroy and surveillance policies, as well
as control in antibiotic prescription.
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Figure 1: 𝐸-test MIC value of colistin. (a) Colistin-susceptible A. baumannii (interpretative criteria; susceptible (S), ≤2 𝜇g/ml). (b) Colistin-
resistant A. baumannii (interpretative criteria; resistant (R), ≥4 𝜇g/ml). Colistin sulfate (CS), ranging from 0.016 to 256mg/ml produced by
Liofilchem SRL, Roseto degli Abruzzi, Italy.
Integron-positive A. baumannii isolates showed higher
antibiotic resistance rate compared to integron-negative
strains. All the isolates with class II integron had a significant
relationship with resistance to all the tested antibiotics which
could be due to the gene cassettes that encoded resistance
to these antibiotics. According to our results, there was a
significant correlation between the presence of class I, II,
and III integrons and resistance to CAZ. Lin et al. [28]
and Mirnejad et al. [29] observed a significant correlation
between the presence of integrons and resistance to CP,
ofloxacin, cefepime, CAZ, aztreonam, AN, and norfloxacin.
Koeleman et al. indicated a significant relationship between
the presence of integrons and resistance to AN, CP, and
CAZ [30]. The results of Gaur et al. confirmed the results
of our study and showed correlation between the presence
of integrons and resistance to AN, cefepime, and CP [31]. In
cases where significant relationships between the integrons
and antimicrobials resistance were not detected, resistance
could be attained by resistance elements that reside onMGEs,
such as plasmids, TEs, and phages, indicating substantial
HGT from other bacteria [32].
5. Conclusion
In general, our results showed that different classes of inte-
grons are commonly spread among A. baumannii strains and
these genomic segments can play an important role in the
acquisition of MDR and XDR A. baumannii. In this study,
regardless of the presence or lack of resistance genes, strong
association was observed between the presence of class II
integrons and a decreased sensitivity to the many classes of
antibiotics which could be challenging, since these structures
can move among strains and consequently become resistant
to new antimicrobials. So, monitoring drug resistance in
A. baumannii isolates with the use of int gene PCR is
very important to plan specific infection control measures
to prevent the spread of MDR-AB and XDR-AB in Iran’s
hospitals.
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